| Revenue growth | H1 revenue +31%; Q2 +33% YoY |
|---|---|
| Margins | Gross margin 62.9% H1; EBITDA margin 33.2% (+780bps) |
| Order book | Healthy order book and key customer commitments stated |
| Demand visibility | CDMO order book healthy; strong internal pipeline cited |
Growth
Q2 revenue ₹2,206 Cr (+33% YoY), CDMO +75% to ₹904 Cr. Affordable Medicines +15% to ₹1,302 Cr. Q2 PAT ₹441 Cr (+126%).
Outlook
LB-4 fermentation (>400kL) commissioning by 3QFY27; KRKA JV Phase-I blocks mid-2027. Pending acquisitions of 60% Galenvs and 52% SI&C Resins.
Risks
Operating cash flow fell 26% to ₹805 Cr on strategic inventory build. Bio revenue down 38% in Q2. ARV revenue flat (+2%).
Investor Presentation filed with BSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,170.00
- Market cap
- ₹1,17,248 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 107.2×Sector 46.1×
- Promoter holding
- 27.47%+0.00% QoQ
- FII holding
- 30.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Results Update
Laurus Labs reported H1 FY27 revenue of ₹4,233 Cr and EBITDA of ₹1,406 Cr. The company acquired Galenvs Sciences and SI&C Resins to expand CDMO capabilities.
- SPPS peptide synthesis capacity
- 16000 L
Laurus Labs Dividend
Laurus Labs approved a Re. 1.00 per share interim dividend for FY 2026-27. Record date is November 6, 2026; payment on or after November 19, 2026.
Laurus Labs Management Change
Laurus Labs appointed Mr. Kundan Kumar Jha as Joint Company Secretary effective November 1, 2026, following Board approval. The KMP appointment advances the company's succession planning process.
Laurus Labs Acquisition Worth ₹32.5 Cr
Laurus Labs approved acquiring 52% of SI & C Resins for Rs. 32.50 Crore. The acquisition makes SI&C a subsidiary for peptide resin manufacturing.
- Value
- ₹32.50 Cr
Laurus Labs Acquisition Worth ₹35.63 Cr
Laurus Labs approved buying 60% of Canada-based CRO Galenvs Sciences for USD 3.75 million (₹35.63 Cr). The deal adds an oligonucleotide R&D arm and North American presence.
- Value
- ₹35.63 Cr
Laurus Labs Q2 FY27 Results: Net Profit ₹436.2 Cr, Up 124.3% YoY
Laurus Labs Ltd reported revenue from operations of ₹2,206 Cr (+33.4% YoY) and net profit of ₹436.2 Cr (+124.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹436.2 Cr · +124.3% YoY